Ketamine Metabolites Enantioselectively Decrease Intracellular D-Serine Concentrations in PC-12 Cells
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
D-Serine is an endogenous NMDA receptor co-agonist that activates synaptic NMDA receptors modulating neuronal networks in the cerebral cortex and plays a key role in long-term potentiation of synaptic transmission. D-serine is associated with NMDA receptor neurotoxicity and neurodegeneration and elevated D-serine concentrations have been associated with Alzheimer's and Parkinsons' diseases and amyotrophic lateral sclerosis. Previous studies have demonstrated that the ketamine metabolites (rac)-dehydronorketamine and (2S,6S)-hydroxynorketamine decrease intracellular D-serine concentrations in a concentration dependent manner in PC-12 cells. In the current study, PC-12 cells were incubated with a series of ketamine metabolites and the IC50 values associated with attenuated intracellular D-serine concentrations were determined. The results demonstrate that structural and stereochemical features of the studied compounds contribute to the magnitude of the inhibitory effect with (2S,6S)-hydroxynorketamine and (2R,6R)-hydroxynorketamine displaying the most potent inhibition with IC50 values of 0.18 ± 0.04 nM and 0.68 ± 0.09 nM. The data was utilized to construct a preliminary 3D-QSAR/pharmacophore model for use in the design of new and more efficient modulators of D-serine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“intracellular and extracellular D-serine levels in PC-12 cell cultures were reduced by (2R,6R; 2S,6S)-HNK with IC50 values of 0.68 ± 0.09 nM and 0.18 ± 0.04 nM respectively (Singh et al., 2016).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Singh et al., 2016
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“This effect was also observed after the administration of (R,S)-Ket and was associated with (R,S)-Ket’s antidepressant activity in the Wistar rat [8,9].”
BackgroundLong-term potentiation depends on release of d-serine from astrocytes
Henneberger, C., Papouin, T., Oliet, S. H. R., & Rusakov, D. A. (2010) · Nature · doi:10.1038/nature08673 · Cited by 1,389
Synaptic and Extrasynaptic NMDA Receptors Are Gated by Different Endogenous Coagonists
Papouin, T., Ladépêche, L., Ruel, J., Sacchi, S., Labasque, M., Hanini, M., Groc, L., Pollegioni, L., Mothet, J.-P., & Oliet, S. H. R. (2012) · Cell · doi:10.1016/j.cell.2012.06.029 · Cited by 754
Domino, E. F., & Warner, D. S. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181ed09a2 · Cited by 520 · cited 1×
“(rac)-Ketamine (Ket) is a chiral phencyclidine derivative that produces rapid and short-lived anesthesia via inhibition of the N-methyl-D-aspartate (NMDA) receptor [1,2].”
Backgroundd‐Amino acids in the brain:d‐serine in neurotransmission and neurodegeneration
Wolosker, H., Dumin, E., Balan, L., & Foltyn, V. N. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06515.x · Cited by 309 · cited 1×
“Recent studies have associated D-serine with NMDA receptor neurotoxicity and neurodegeneration [11,24] and elevated D-serine concentrations have been associated with Alzheimer’s and Parkinsons’ Fig 3.”
BackgroundZarate, C. A., Brutsche, N., Laje, G., Luckenbaugh, D. A., Venkata, S. L. V., Ramamoorthy, A., Moaddel, R., & Wainer, I. W. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.004 · Cited by 282 · cited 1×
“patients suffering from treatment resistant major depressive disorder (MDD) and bipolar depression produced by subanesthetic dosing of (R,S)-Ket [6].”
BackgroundSelf-citationNeuron-derived D-Serine Release Provides a Novel Means to Activate N-Methyl-D-aspartate Receptors
Kartvelishvily, E., Shleper, M., Balan, L., Dumin, E., & Wolosker, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512927200 · Cited by 279 · cited 13×
“Ket Metabolites Reduce Intracellular D-Serine Concentrations The molecular structures of the compounds used in this study are presented in Fig 1.”
BackgroundInfluentialMechanisms of analgesia by gabapentin and pregabalin – Calcium channel α2-δ [Cavα2-δ] ligands
Taylor, C. P. (2009) · Pain · doi:10.1016/j.pain.2008.11.019 · Cited by 257 · cited 1×
“This effect was attributed to decreased intracellular Ca flux resulting from the interaction of gabapentin and (S)-pregabalin with the α2-δ subunit of the voltage-gated Cavα2-δ calcium channel [31].”
BackgroundShleper, M., Kartvelishvily, E., & Wolosker, H. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3190-05.2005 · Cited by 216 · cited 1×
“Recent studies have associated D-serine with NMDA receptor neurotoxicity and neurodegeneration [11,24] and elevated D-serine concentrations have been associated with Alzheimer’s and Parkinsons’ Fig 3.”
Background
Cited by
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Self-citationMatveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Mechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Gould, T. D., Zarate, C. A., & Thompson, S. M. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052811 · Cited by 133
Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications
Highland, J. N., Zanos, P., Riggs, L. M., Georgiou, P., Clark, S. M., Morris, P. J., Moaddel, R., Thomas, C. J., Zarate, C. A., Pereira, E. F. R., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000149 · Cited by 92
“The mTOR pathway, a downstream target of BDNF/ TrkB, has also been shown to be increased byHNKs (Paul et al., 2014; Singh et al., 2016; Fukumoto et al., 2019; Lumsden et al., 2019).”
BackgroundSelf-citationPradhan, B., Mitrev, L., Moaddell, R., & Wainer, I. W. (2018) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2018.03.006 · Cited by 63
Self-citationHighland, J. N., Morris, P. J., Zanos, P., Lovett, J., Ghosh, S., Wang, A. Q., Zarate, C. A., Thomas, C. J., Moaddel, R., & Gould, T. D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118812095 · Cited by 62
“Although early studies classified (2R,6R;2S,6S)-HNK as an inactive metabolite due to its lack of anesthetic effects (Leung and Baillie, 1986), more recent studies have established the biological activity of this metabolite (Cavalleri et al., 2018; Chou et al., 2018; Faccio et al., 2018; Ho et al., 2018; Kroin et al.,…”
Self-citationLavender, E., Hirasawa-Fujita, M., & Domino, E. F. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112631 · Cited by 58
Gut Microbial Dysbiosis and Cognitive Impairment in Bipolar Disorder: Current Evidence
Dai, W., Liu, J., Yan, Q., Teng, Z., Li, S., Yuan, H., Huang, J., Xiang, H., Tang, H., Wang, B., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.893567 · Cited by 46
“Furthermore, ketamine metabolites (rac)dehydronorketamine and (2S,6S)-hydroxynorketamine decrease intracellular D-serine concentrations in a concentration dependent manner in PC-12 cells (Singh et al., 2016).”
BackgroundKetamine and Major Ketamine Metabolites Function as Allosteric Modulators of Opioid Receptors
Gomes, I., Gupta, A., Margolis, E. B., Fricker, L. D., & Devi, L. A. (2024) · Molecular Pharmacology · doi:10.1124/molpharm.124.000947 · Cited by 31
Aleksandrova, L. R., Wang, Y. T., & Phillips, A. G. (2017) · Chronic Stress · doi:10.1177/2470547017743511 · Cited by 20
“It is also important to consider other, unique effects of (2S,6S;2R,6R)-HNK such as a7-nAchR antagonism(41) and attenuation of Dserine levels, which could possibly lead to an indirect inhibition of NMDAR function.(64) Therefore, (2R,6R)HNK could contribute to ketamine’s unique ability to increase the AMPA to NMDA rece…”
BackgroundInfluentialChen, B. K., & Denny, C. A. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109345 · Cited by 19
Lilius, T. O., Viisanen, H., Jokinen, V., Niemi, M., Kalso, E. A., & Rauhala, P. V. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12941 · Cited by 18
Sandbaumhüter, F. A., Theurillat, R., & Thormann, W. (2017) · Electrophoresis · doi:10.1002/elps.201700016 · Cited by 17
Subchronic administration of (R,S)-ketamine induces ketamine ring hydroxylation in Wistar rats
Moaddel, R., Sanghvi, M., Ramamoorthy, A., Jozwiak, K., Singh, N., Green, C., O’Loughlin, K., Torjman, M., & Wainer, I. W. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.03.030 · Cited by 17
Self-citationFaccio, A. T., Rupérez, F. J., Singh, N., Angulo, S., Tavares, M. F. M., Bernier, M., Barbas, C., & Wainer, I. W. (2018) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2018.03.008 · Cited by 14
Self-citationKim, E. J., Felsövályi, K., Young, L. M., Shmelkov, S. V., Grunebaum, M. F., & Cardozo, T. J. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4958-9 · Cited by 10
Ma, M., Ren, Q., Fujita, Y., Yang, C., Dong, C., Ohgi, Y., Futamura, T., & Hashimoto, K. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4700-z · Cited by 11
“A recent study has demonstrated that (R)-ketamine and its metabolite (2R,6R)-hydroxynorketamine decrease both intracellular and extracellular D-serine levels in PC12 and 1321N1 cells (Singh et al. 2015, 2016), suggesting that (R)ketamine and its metabolite affect D-serine transport.”
BackgroundGold, N. D., Mallard, A. J., Hermann, J. C., Zeifman, R. J., Pagni, B. A., Bogenschutz, M. P., & Ross, S. (2023) · Journal of Palliative Medicine · doi:10.1089/jpm.2022.0604 · Cited by 6
“121 While ketamine blocks glutamate directly at NMDA receptor sites at high anesthetic doses, it induces an acute surge of glutamate activity at sub-anesthetic, or psychedelic, doses, 122 and it is not understood how this acute surge may affect ALS pathology.”
Aleksandrova, L. R. (2019) · cIRcle (University of British Columbia) · doi:10.14288/1.0383291
“HNK does not directly inhibit NMDARs at clinically relevant concentrations, it is possible that its mechanism of action involves indirect NMDAR inhibition elicited by a reduction in D-serine co-agonist levels, a theory that awaits validation in vivo (Singh et al., 2016).”
BackgroundInfluentialKetamine prolongs survival in symptomatic SOD1-G93A mice
Stanford, J. A., Macaluso, M., Barohn, R. J., & Peck, L. (2021) · RRNMF Neuromuscular Journal · doi:10.17161/rrnmf.v2i2.15108
Emergence of Ketamine as a Rapid Acting Antidepressant: Mechanistic Insights and Future Directions
Singh, A., & Bedi, P. M. S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.99765
Drug Repurposing Patent Applications October: December 2021
Mucke, H. A. (2022) · Assay and Drug Development Technologies · doi:10.1089/adt.2022.002
“The inventors propose treatment with ketamine, a dissociative drug which is also known as an NMDA receptor antagonist, but has additional neuroprotective properties, such as reduction of intracellular concentrations of D-serine 25 (a co-agonist at the NMDA receptor) and several others.”
Ketamine and its metabolites—Mechanism of action
Kneebusch, J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29930-8.00010-2
Metadata
- Authors
- Singh, N. S., Rutkowska, E., Plazinska, A., Khadeer, M., Moaddel, R., Jozwiak, K., Bernier, M., & Wainer, I. W.
- Affiliations
- National Institutes of Health (US)
- Medical University of Lublin (PL)
- Corresponding author
- Wainer, Irving W.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-04-20
- Volume
- 11
- Issue
- 4
- Pages
- e0149499
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4838237
- OpenAlex
- W2339134523
- Cited by
- 23
- References
- 33
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 4 · 2020: 2 · 2018: 6 · 2017: 4 · 2016: 1
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- public-domain
- creativecommons.org/publicdomain/zero/1.0/ (vor)
- Locations
- PLoS ONE (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fundacja na rzecz Nauki Polskiej
- National Institutes of Health
- National Institute on Aging
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- ketamine metabolites, D-serine, enantiomers, hydroxynorketamine, dehydronorketamine, NMDA receptor co-agonist, PC12 cells, stereochemistry, 3D-QSAR, pharmacophore model, neurodegeneration
- MeSH terms
- Animals, Ketamine, Models, Molecular, Serine, Stereoisomerism, Blotting, Western, Minor Histocompatibility Antigens, PC12 Cells, Protein Transport, Amino Acid Transport System ASC, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.